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disorder (OR 20.1: CI 12.3-33.1) significantly increased the use of antipsychotic 
medication in children with ADHD. CONCLUSIONS: Stimulants remained the 
mainstay of treatment for ADHD in children, although its use decreased after 
2006 which is consistent with other studies. Antipsychotic use was less common 
but increased significantly in recent years.  
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OBJECTIVES: Prescription drug abuse has emerged as a major public health 
threat over the past decade. The role of polydrug use (PDU) of psychotherapeutic 
drugs is currently not well understood in prescription drug abuse (defined as 
nonmedical use of prescription drugs-NMUPD). This study aims to characterize 
NMUPD and examine the role of PDU in contributing to prescription drug abuse. 
METHODS: The National Survey of Drug Use and Health (NSDUH-2010) was 
utilized to study a population of noninstitutionalized, civilian Americans, aged 
12 years and over for NMUPD. NMUPD was defined as the act of consuming a 
drug from any of the four drug classes (pain relievers, stimulants, tranquilizers 
and sedatives) without a valid prescription or with a prescription for the 
experience or feeling it caused. PDU was defined as the use of two or more 
prescription psychotherapeutic drugs within the past one year. Associations 
between PDU and NMUPD were tested with respect to demographic and socio-
economic factors. RESULTS: Out of a sample of 5166 individuals who were taking 
psychotherapeutic drugs, about 29% (n=1493) were engaged in PDU. About 4.47% 
(n=231) of the sample fit the criteria for NMUPD. About 6.50% (n=97) of the PDU 
sample (n=1493) were engaged in NMUPD. NMUPD was found to be more 
common among polydrug-users than monodrug-users (6.5% vs. 3.65%). A Chi-
Square test for independence showed a significant association between PDU and 
NMUPD (χ2=20.167, p<0.0001). Demographically, a majority of the polydrug-users 
with NMUPD were in the age-group 18-25 years (55%), female (54.64%), single 
(83.51%), nonhispanic white (77.32%), with high school graduation (60.82%) and 
income less than $10,000 annually (68.04%). CONCLUSIONS: PDU is a notable and 
legitimate risk factor for NMUPD. NMUPD among polydrug-users appears to be 
more prevalent in a population that is young, mostly female, nonhispanic white, 
with limited income and education.  
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OBJECTIVES: Psychotropic polypharmacy is common in pediatric Attention 
Deficit/Hyperactivity Disorder (ADHD). This study examined determinants of the 
long acting stimulant (LAS) and atypical antipsychotic (AAP) polypharmacy in 
children and adolescents with ADHD. METHODS: This study used 4 years 
(January 2004 to December 2007) of IMS LifeLink™ claims data involving 6-16 
years old children with ADHD and at least one LAS prescription between July 
2004 to December 2006 and continuous eligibility 6 months before and 1 years 
after the index LAS prescription. Polypharmacy was defined as the concurrent 
prescription for LASs and AAPs for at least 14 days within the 365 days after the 
index LAS claim. Multiple logistic regression analysis was performed to examine 
predictors of LASs and AAPs polypharmacy in pediatric ADHD. RESULTS: The 
study cohort consisted of 39,981 children and adolescents. Of these, 1,560 (3.90%) 
received LAS and AAP polypharmacy and the rest 38,421 (96.10%) received LAS 
monotherapy. Multivariate logistic regression analysis revealed that factors 
positively associated with psychotropic polypharmacy were: male, year of cohort 
entry (2005 and 2006), initiation of LAS in summer, psychiatrist visit, depression, 
conduct disorder, enuresis, tics, bipolar disorder, oppositional disruptive 
disorder, psychosis and pervasive developmental disorders, use of psychotropic 
medications from other drug class such as α2-agonists, antidepressants, mood 
stabilizers and other miscellaneous medications, and mental health-related 
hospital visit in the past 6 months. Children with public health insurance, those 
residing in Midwest and West regions, those who initiated use of index LAS in 
spring, those seen by pediatrician, and those with comorbidity of substance 
abuse and dependence were less likely to receive LAS and AAP polypharmacy. 
CONCLUSIONS: Various patient, clinical and treatment factors were associated 
with the receipt of polypharmacy among ADHD youths. Understanding of these 
factors can help to manage psychotropic polypharmacy and improve quality of 
care in pediatric ADHD.  
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OBJECTIVES: The study examined the prevalence and factors associated with 
concurrent use of long acting stimulants (LAS) and atypical antipsychotic agents 
among children and adolescents who initiated LAS medications for Attention 
Deficit/Hyperactivity Disorder (ADHD). METHODS: The study involved 
retrospective longitudinal analysis of 2003-2007 Medicaid Analytical eXtract 
(MAX) data of four US states. The study focused on children and adolescents 
aged 6 to 17 years, diagnosed with ADHD, and who initiated LAS from July 2003 
to December 2006. Concurrent use was defined as receipt of both medications 
together at least for 14 days. The study cohort was followed uniformly for one 
year after the initiation of LAS medications to examine the concurrent use. 
Descriptive analysis was conducted to examine the utilization pattern. Multiple 
logistic regression analysis within the conceptual framework of Andersen 
behavioral model was conducted to examine determinants of concurrent use 
with LAS use only as a reference group. RESULTS: Among the 61,793 children 
and adolescents who initiated ADHD treatment with LAS, 11, 866 (19.20%) 
received LAS and atypical antipsychotics concurrently. Risperidone was 
frequently used concurrently with LAS in children. The multiple logistic 
regression revealed that children and adolescents with male gender, black race, 
and foster care benefits were more likely to receive LAS and atypical 
antipsychotics concurrently than their counterparts. Moreover, FDA approved 
indications such as schizophrenia, bipolar disorder, and psychosis and non-
approved indications such as oppositional defiant disorder, pervasive 
developmental disorder, tic disorder, and personality disorder determined  
the concurrent use. CONCLUSIONS: Almost 1 in 5 children and adolescent 
received LAS and atypical antipsychotics concurrently. In addition to  
FDA approved indications, non-approved indications determined the concurrent 
use. There is urgent need to evaluate the safety and efficacy of concurrent use of 
LAS and atypical antipsychotics in children and adolescents for various 
indications.  
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OBJECTIVES: Depression is a major public health concern with significant 
patient and societal burden. However, many patients with depressive symptoms 
do not receive treatment. This study examined nationally representative 
estimates of the prevalence of depressive symptoms and factors associated with 
treatment. METHODS: A cross-sectional, retrospective analysis of adults age ≥18 
represented in the 2005-2010 National Health and Nutrition Examination Survey 
(NHANES) data (n=15,838; weighted n=194,685,449) who responded to the Patient 
Health Questionnaire (PHQ-9) was conducted. Depressive symptoms were 
defined by PHQ-9 score ≥5. Depression treatment was defined as receiving either 
antidepressants or psychotherapy. Multivariate logistic regression analyses using 
population weights were performed to identify factors associated with having 
depressive symptoms. Among the group of patients with moderate to severe 
depression, similar models assessed factors associated with receipt of treatment. 
RESULTS: The prevalence of depressive symptoms increased gradually from 
2005-2010 (21.4% in 2005-2006; 25.6% in 2007-2008; and 26.1% in 2009-2010). 
Among patients with moderate to severe depressive symptoms, over one-third 
(weighted n=6,132,302; 37.0%) received either antidepressants or psychotherapy 
treatment. Multivariate results found that comorbidities (high blood pressure, 
diabetes, asthma, arthritis, heart failure, stroke, COPD, and obesity), previous 
hospitalization, having no health insurance, seeing a mental professional, 
receiving antipsychotic drugs, female, Hispanic ethnicity, in poverty status, and 
age of 20-59 (vs. age <20) were significant factors associated with having 
depressive symptoms (P<0.05). Among patients with moderate to severe 
depression, comorbidities (asthma and cancer), seeing a mental professional, 
receiving antipsychotic drugs, female, and Non-Hispanic White race were 
statistically significantly associated with receipt of treatment (P<0.05). 
CONCLUSIONS: Although the prevalence of depression symptoms is high and 
growing in the U.S. population, only a small portion of patients with moderate to 
severe depression received treatments. Additionally, significant disparities by 
ethnicity and use of mental professionals appear to be associated with the 
likelihood of receiving treatment.  
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OBJECTIVES: To examine the impact of atypical antipsychotic use on the 
persistence of long acting simulants (LAS) in children and adolescents with 
Attention Deficit/Hyperactivity Disorder (ADHD). METHODS: The study involved 
retrospective longitudinal analysis of 2003-2007 Medicaid Analytical eXtract 
(MAX) data of four US states. The study focused on children and adolescents 
aged 6 to 17 years, diagnosed with ADHD, and who initiated LAS after 6 months 
washout period. Concurrent use was defined as receipt of both medications 
together at least for 14 days. The persistence of LAS was defined as number of 
days to discontinuation of index LAS. The patients were censored at the 
discontinuation of index LAS or end of study period whichever comes first. 
Descriptive analysis was used to examine demographic, service related, and 
clinical characteristics of study sample. Accelerated Failure Time (AFT) 
regression was conducted to examine the determinants of persistence of LAS. 
RESULTS: Among the 61,793 children and adolescents who initiated LAS for 
ADHD 9,902 (16.03%) received LAS and atypical antipsychotic concurrently. Most 
of the study sample was children aged between 6-12 years, males, and whites. 
The mean duration of LAS treatment was longer (200 days) among concurrent 
users than only LAS users (143 days). The AFT regression found that concurrent 
users had 45% longer (STR, 1.45; 95% CI, 1.41-1.49) LAS persistence than those 
using LAS only. Adolescents and non-whites had shorter LAS treatment 
persistence than their counterparts after controlling for demographics, service 
related, and clinical factors. CONCLUSIONS: The concurrent users had longer 
LAS treatment continuity than LAS only users. The addition of the atypical 
